http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
BANG, WON GI,Chung, Nam Hyun,Lee, Il Seok,Song, Hee Sang 한국환경농학회 2000 한국환경농학회지 Vol.19 No.5
The bioremediation is an economic technology to remove the organopollutants from soil. It is often found that the remediation could not remove the compounds below the levels determined by vigorous extractions as required by regulatory agencies. The reason for the reduced bioavailability with increasing time of aging has been accredited to the sequestration of the compounds in remote sites within or between soil particles. Then, the aging could be defined as the time-dependent sequestration. Partitioning and entrapment have been suggested as mechanism for aging. The rate and extent of the sequestration varies among dissimilar soils. The bioavailability of aged pollutants in soil could be measured by bioassays, mild solvent extraction, and soild-phase extractions. The sequestration could be affected by many factors including various soil properties, wetting and drying cycle, and the presence of cosolutes and NAPLs etc. The bioavailability and sequestration should be considered to determine the environmentally acceptable endpoint.
Bang, Ji-In,Lee, Eun Seong,Kim, Tae-Sung,Kim, Seok-Ki 大韓核醫學會 2015 핵의학 분자영상 Vol.49 No.1
<P>As the survival rate of cancer patients has increased over the last few decades, the risk of cancer survivors developing second primary malignancies has gained attention. We report two rare cases of second primary hematologic malignancy detected by (18)F-fluorodeoxyglucose (F-18 FDG) positron emission tomography/computed tomography (PET/CT) during follow-up for primary solid malignancies. Acute lymphoblastic leukemia developed in a breast cancer patient and non-Hodgkin lymphoma in an anal cancer patient. F-18 FDG PET/CT findings led to the diagnosis of unexpected second primary hematologic malignancy in cancer survivors in these two cases.</P>
Sang-Hun Kim(김상현),Kwang-Youn Kim(김광연),Sun-Nyoung Yu(유선녕),Seul-Ki Park(박슬기),In-Seok Kwak(곽인석),Moon-Soo Rhee(이문수),Byung-Ho Bang(방병호),Sung-Sik Chun(전성식),Soon-Cheol Ahn(안순철) 한국생명과학회 2012 생명과학회지 Vol.22 No.11
Pipernonaline은 후추나무과에 속하는 필발(Piper longum Linn.)의 유도체로서 전립선 암세포에 대한 항암활성이 보고되고 있다. 하지만 실제 암세포 내에서 생물학적 정보를 가진 수 많은 유전자들에 대한 발현이 어떻게 이루어지고 있는지 알려진 바가 없다. 본 연구에 사용된 microarray 분석은 동시에 수 만개 이상의 유전자 발현양상을 한번에 관찰할 수 있는 기술로서 특정 질병의 유전학적 특성과 기전 연구를 더 광범위하게 연구 할 수 있는 기술이다. 본 연구에서는 전립선 암세포인 PC-3 세포에 pipernonaline을 처리하여 cDNA microarray를 실시하였다. 이후, DAVID database를 이용하여 gene ontology의 Biological Process를 분석하여 세포사멸과 세포주기, 세포성장 및 증식에 관련된 유전자들을 우선적으로 분석하였다. 그 결과, 세포주기관련 256개, 세포사멸관련 197개, 세포성장 및 증식관련에 154개의 유전자가 확인 되었다. 이러한 결과는 pipernonaline은 전립선 암세포 내에 존재하는 생물학적 신호전달체계에 관련된 유전자 발현을 조절함으로써 항암활성을 나타내 것을 알 수 있었고, 이후 이러한 microarray의 추가적인 분석은 암세포 내 새로운 유전자의 탐색 및 메커니즘을 규명하는데 유용하게 사용할 수 있을 것으로 사료된다. It has been reported that pipernonaline isolated from Piper longum Linn. has a wide biochemical and pharmacological effect, including antitumor activity in prostate cancer PC-3 cells. However, its mechanism and expression pattern of many genes involved in biological functions are not clearly understood. To perform the gene expression study in PC-3 cells treated with pipernonaline, a cDNA microarray chip composed of 44,000 human cDNA probes was used. As a result, cell cycle-related genes, apoptosis-related genes, and cell proliferation/growth-related genes have been identified in gene ontology of the DAVID database. These results suggest that pipernonaline has antitumor activity by regulating the expression pattern of genes involved in biological signaling pathway in prostate cancer PC-3 cells. Further, additional analysis of these microarray data can be a useful tool to identify the mechanism and discovery of novel genes in cancer therapy.
( Sang Yu Oh ),( Bo Ryung Park ),( Byung Uk Lee ),( Jae Ho Park ),( Byung Gyu Kim ),( Seok Won Jung ),( In Du Jeong ),( Sung-jo Bang ),( Jung Woo Shin ),( Neung Hwa Park ),( Yun Im Lee ) 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: Rare data are available on the comparison of tenofovir (TDF) and entecavir (ETV) therapy in chronic hepatitis B patients with baseline high viral load (HVL) in clinical practice, defined as having hepatitis B virus (HBV) DNA >8 log10 copies/mL (7.3 log10 IU/mL). Methods: We performed a retrospective analysis of the efficacy of TDF therapy, as compared to that of ETV therapy, in patients with HVL. A matched study population was constructed to compare the antiviral efficacy of TDF therapy and ETV therapy by a propensity score analysis. Results: Three hundreds two patients were selected after matching propensity score with 1:1 ratio. Virologic response (VR) was observed in 63.6% (96/151) of patients in the TDF group and in 64.2% (97/151) of the patients in the ETV group. The VR rates were not different between the TDF and ETV groups (51.5 vs. 51.4% at month 12, and 72.1 vs. 69.2% at month 24; log rank P = 0.432). During therapy, 70.2% of patients in the TDF group, and 74.8% of patients in the ETV group had partial VR, respectively (P=0.367). ALT normalization rates also did not differ between both the treatment groups (94.3% and 92.1% in the TDF and ETV therapy groups, respectively; P = 0.838). Nineteen patients experienced a virological breakthrough. Among them, 7 patients (4.6 %) was in the TDF group and 12 patients (7.9 %) were in the ETV group (P = 0.236). During therapy, 21.2% (28 of 132) of patients in the TDF group, and 19.1% (25 of 131) of patients in the ETV group achieved HBeAg seroconversion, respectively (P = 0.667). In multivariate analysis, absolute HBV DNA level at baseline (P<0.001), HBeAg-positive status (P< 0.001) and ALT levels at baseline (P =0.044) were significantly associated with VR. Conclusions: In patients with HVL >8 log10 copies/mL (7.3 log10 IU/mL), virological and biochemical responses were similar between ETV and TDF therapy groups in CHB patients. Therefore, either ETV or TDF are recommended to use as the first-line nucleoside analogues in patients with HVL..
( Sang Yu Oh ),( Bo Ryung Park ),( Byung Uk Lee ),( Jae Ho Park ),( Byung Gyu Kim ),( Seok Won Jung ),( In Du Jeong ),( Sung-jo Bang ),( Jung Woo Shin ),( Neung Hwa Park ),( Yun Im Lee ) 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: Either entecavir (ETV) or tenofovir disoproxil fumarate (TDF) are recommended to use as the first-line nucleoside analogues (NAs) in patients with chronic hepatitis B (CHB) due to their potent viral suppression with a lower risk of drug resistance and excellent preventive effect for hepatocellular carcinoma (HCC) development. However, the effects of ETV and TDF on HCC development in CHB patients have not been fully examined. Methods: The aims of the current study were therefore to compare the effects of ETV and TDF therapy on HCC development in CHB patients in clinical practice. A total of 1,412 ETV-naïve patients and 1,318 TDF-naı¨ve patients were enrolled into the study. Results: The baseline characteristics of both groups were no significant difference. Virological and biochemical responses were similar between the two therapy groups over time. During a median 26 months of follow-up (range 1.0-60 months), 126 patients (4.6%) developed HCC. The 1-, 2-, 3- and 5-year cumulative HCC incidence rates in all cases were 2.2%, 3.8%, 5.1% and 9.9%, respectively. There was no significant difference in cumulative rates of HCC carcinoma (HCC) development (log-rank P = 0.357) between the two therapy groups. Multivariate analysis showed that male, older age, cirrhosis, lower albumin levels and HBeAg-positve status were independently associated with HCC development. Conclusions: HCC incidence and virological response were similar between ETV and TDF therapy groups in CHB patients in clinical practice. Therefore, either ETV or TDF are recommended to use as the first-line nucleoside analogues in patients with CHB due to their potent viral suppression and similar effect for HCC development.
Bang, Oh Young,Yeo, Seung Hyeon,Yoon, Jung Han,Seok, Jung Im,Sheen, Seung Soo,Yoon, Sa Rah,Kim, Gyeong Moon,Chung, Chin Sang,Lee, Kwang Ho S. Karger AG 2007 Cerebrovascular Diseases Vol.24 No.6
<P><I>Background:</I> Lacunar stroke has been defined as an infarct <15 mm in diameter in the presence of symptoms of lacunar syndromes. We investigated a new approach in predicting whether a deep infarct is caused by small arterial occlusion. <I>Methods:</I> A total of 319 consecutive patients with acute symptomatic infarcts within the striatocapsular territory underwent diffusion-weighted imaging (DWI) and diagnostic workups, including vascular and cardiological studies. Predictors for nonlacunar mechanisms were evaluated by logistic regression analysis, with the size of infarct (1-mm increase) and stroke syndrome (traditional vs. atypical lacunar syndrome vs. cortical syndrome) graded rather than dichotomized. <I>Results:</I> Amongst the 171 patients who did not meet the established criteria for lacunar stroke, that is, deep infarct of ≥15 mm or presenting symptoms of nontraditional lacunar syndrome, a documented etiology could not be determined in 97 (56.7%) patients. In contrast, amongst the 148 patients who met the criteria, 27 (18.2%) had nonlacunar mechanisms. Logistic regression analysis identified the variables that predicted nonlacunar stroke mechanisms with statistical significance as nontraditional lacunar syndromes (OR 2.19 for atypical lacunar syndrome, and OR 6.72 for cortical syndrome), infarct size on DWI (OR 1.05 per 1-mm increase), and unilateral multiple deep infarcts on DWI (OR 2.22, p < 0.05 in all cases). Receiver operating characteristic curves showed that discrimination power of the model derived from logistic regression analysis (grading system) was better than that of the previously established dichotomizing criterion in predicting nonlacunar mechanisms (p = 0.004). <I>Conclusions: </I>A clinically significant proportion of clinical MRI lacunae are associated with underlying nonlacunar mechanisms. Decisions regarding the extent of diagnostic procedures in patients with subcortical infarcts can be guided by the point value in terms of the stroke syndrome and infarct patterns, as well as the size of infarct.</P><P>Copyright © 2007 S. Karger AG, Basel</P>
( Sang Yu Oh ),( Bo Ryung Park ),( Byung Uk Lee ),( Jae Ho Park ),( Byung Gyu Kim ),( Seok Won Jung ),( In Du Jeong ),( Sung-jo Bang ),( Jung Woo Shin ),( Neung Hwa Park ),( Yun Im Lee ) 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: Tenofovir (TDF) therapy has been recommended as a rescue strategy for chronic hepatitis B (CHB) patients with nucleos(t)ide (NA) resistance. Unfortunately, after sequential NA monotherapy in CHB patients with lamivudine (LAM) resistance, multidrug resistance (MDR) developed in a substantial number of patients. Very limited data are available on the comparison of TDF therapy between single drug resistant (SDR) and MDR groups in NA-resistant CHB patients. Methods: Of the 269 CHB patients with NA-resistance, 139 were SDR group and 130 were MDR group. A matched study population was constructed to compare the antiviral efficacy of TDF therapy by a propensity score analysis. Results: Two hundreds CHB patients were selected after matching propensity score with 1:1 ratio. The median follow-up period during TDF therapy was 47.3 months (range, 6-59 months). Virologic response (VR) occurred in 188 patients (95 patients in the SDR group and 93 patients in the MDR group) during the treatment period. The VR rate was lower in the MDR group than in the SDR group but statistically insignificant (74.3% vs. 85.6% at month 12, and 87.4% vs. 92.2% at month 24; log rank P=0.111). Partial virologic response (PVR) rates were not different between both groups (20.0% and 31.0% in the SDR and MDR groups, respectively; P = 0.105). The rates of ALT normalization and HBeAg seroconvesion also did not differ between both groups (P>0.05). In multivariate analysis, absolute HBV DNA level at the start of TDF rescue treatment (P<0.001; OR, 0.715; 95% CI, 0.646-0.791) was only significantly associated with VR. Conclusions: TDF rescue therapy has comparable efficacy in the SDR and MDR CHB patients, and the presence of MDR did not alter the response rates. HBV DNA level at the start of TDF rescue therapy was the only predictor of subsequent VR.